A novel once-daily oral PCSK9 inhibitor lowered LDL by up to 60% at 24 weeks in patients with heart disease or at high risk ...
A new U.S. study from Johnson & Johnson (NYSE: JNJ) reveals that most people living with psoriasis — and their healthcare providers — strongly prefer effective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback